CYP2B6 Genotype Alters Abstinence Rates in a Bupropion Smoking Cessation Trial

[1]  Jason Gong,et al.  Efficacy of Varenicline, an 42 Nicotinic Acetylcholine Receptor Partial Agonist, vs Placebo or Sustained-Release Bupropion for Smoking Cessation A Randomized Controlled Trial , 2006 .

[2]  David Gonzales,et al.  Varenicline, an α4β2 Nicotinic Acetylcholine Receptor Partial Agonist, vs Sustained-Release Bupropion and Placebo for Smoking Cessation: A Randomized Controlled Trial , 2006 .

[3]  A. S. Gross,et al.  Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: Effect of induction by rifampin and ethnicity , 2006, Clinical pharmacology and therapeutics.

[4]  M. Eichelbaum,et al.  Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz , 2005, Pharmacogenetics and genomics.

[5]  J. Jefferson,et al.  Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations. , 2005, Clinical therapeutics.

[6]  S. Tiffany,et al.  Effect of sustained-release (SR) bupropion on craving and withdrawal in smokers deprived of cigarettes for 72 h , 2005, Psychopharmacology.

[7]  M. Eichelbaum,et al.  A Natural CYP2B6 TATA Box Polymorphism (–82T→ C) Leading to Enhanced Transcription and Relocation of the Transcriptional Start Site , 2005, Molecular Pharmacology.

[8]  R. Tyndale,et al.  Implications of CYP2A6 Genetic Variation for Smoking Behaviors and Nicotine Dependence , 2005, Clinical pharmacology and therapeutics.

[9]  Amalio Telenti,et al.  Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients , 2005, Pharmacogenetics and genomics.

[10]  Catia Marzolini,et al.  Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study , 2004, AIDS.

[11]  Joo-Youn Cho,et al.  HAPLOTYPE STRUCTURE AND ALLELE FREQUENCIES OF CYP2B6 IN A KOREAN POPULATION , 2004, Drug Metabolism and Disposition.

[12]  M. Eichelbaum,et al.  Multiple Novel Nonsynonymous CYP2B6 Gene Polymorphisms in Caucasians: Demonstration of Phenotypic Null Alleles , 2004, Journal of Pharmacology and Experimental Therapeutics.

[13]  R. Tyndale,et al.  Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians. , 2004, Pharmacogenetics.

[14]  R. Lukas,et al.  Enantioselective Effects of Hydroxy Metabolites of Bupropion on Behavior and on Function of Monoamine Transporters and Nicotinic Receptors , 2004, Molecular Pharmacology.

[15]  M. Neville,et al.  Identification of CYP2B6 sequence variants by use of multiplex PCR with allele-specific genotyping. , 2004, Clinical chemistry.

[16]  S. Oka,et al.  Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens. , 2004, Biochemical and Biophysical Research Communications - BBRC.

[17]  M. Jarvik,et al.  Attenuation of cue-induced cigarette craving and anterior cingulate cortex activation in bupropion-treated smokers: a preliminary study , 2004, Psychiatry Research: Neuroimaging.

[18]  D. Greenblatt,et al.  Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes. , 2004, Pharmacogenetics.

[19]  H. Javitz,et al.  Bupropion SR and counseling for smoking cessation in actual practice: predictors of outcome. , 2003, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[20]  J. Sasse,et al.  Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. , 2003, Pharmacogenetics.

[21]  S. Tonstad,et al.  A multicentre, randomized, double‐blind, placebo‐controlled, 1‐year study of bupropion SR for smoking cessation , 2003, Journal of internal medicine.

[22]  D. Mash,et al.  Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain , 2003, Neuropharmacology.

[23]  H. Jinno,et al.  Functional characterization of cytochrome P450 2B6 allelic variants. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[24]  L. Epstein,et al.  Pharmacogenetic investigation of smoking cessation treatment. , 2002, Pharmacogenetics.

[25]  W. Velicer,et al.  Biochemical verification of tobacco use and cessation. , 2002, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[26]  Jeffrey P. Jones,et al.  An in vivo pilot study characterizing the new CYP2A6*7, *8, and *10 alleles. , 2002, Biochemical and biophysical research communications.

[27]  D. Nelson,et al.  Organization, structure and evolution of the CYP2 gene cluster on human chromosome 19. , 2001, Pharmacogenetics.

[28]  U. Hofmann,et al.  Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. , 2001, Pharmacogenetics.

[29]  M. Damaj,et al.  Bupropion is a nicotinic antagonist. , 2000, The Journal of pharmacology and experimental therapeutics.

[30]  C. Lindley,et al.  Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[31]  N E Morton,et al.  The use of long PCR to confirm three common alleles at the CYP2A6 locus and the relationship between genotype and smoking habit , 2000, Annals of human genetics.

[32]  P. Beaune,et al.  Human CYP2B6: expression, inducibility and catalytic activities. , 1999, Pharmacogenetics.

[33]  Aker,et al.  A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. , 1999, The New England journal of medicine.

[34]  Kiyoshi Inoue,et al.  Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes , 1999, Archives of Toxicology.

[35]  Darrell R. Schroeder,et al.  A Comparison of Sustained-Release Bupropion and Placebo for Smoking Cessation , 1997 .

[36]  R. Tyndale,et al.  A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. , 1997, The Journal of pharmacology and experimental therapeutics.

[37]  J. A. Johnston,et al.  Pharmacokinetics of Bupropion and its Metabolites in Cigarette Smokers versus Nonsmokers , 1997, Journal of clinical pharmacology.

[38]  T Sakaki,et al.  Multiple forms of human P450 expressed in Saccharomyces cerevisiae. Systematic characterization and comparison with those of the rat. , 1996, Biochemical pharmacology.

[39]  L. Epstein,et al.  Role of Functional Genetic Variation in the Dopamine D2 Receptor (DRD2) in Response to Bupropion and Nicotine Replacement Therapy for Tobacco Dependence: Results of Two Randomized Clinical Trials , 2006, Neuropsychopharmacology.

[40]  Stephen M. Stahl,et al.  A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor. , 2004, Primary care companion to the Journal of clinical psychiatry.

[41]  U. Yasar,et al.  Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation , 2003, The Pharmacogenomics Journal.

[42]  S. Shiffman,et al.  The effect of bupropion on nicotine craving and withdrawal , 2000, Psychopharmacology.

[43]  L. Stead,et al.  Anxiolytics and antidepressants for smoking cessation. , 2000, The Cochrane database of systematic reviews.

[44]  D. H. Schroeder,et al.  Pharmacological significance of the species differences in bupropion metabolism. , 1987, Xenobiotica; the fate of foreign compounds in biological systems.